Literature DB >> 22142164

Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.

Muhammad Zaeem Noman1, Yosra Messai, Thibault Carré, Intissar Akalay, Marine Méron, Bassam Janji, Meriem Hasmim, Salem Chouaib.   

Abstract

Hypoxia, a common feature of solid tumors and one of the hallmarks of tumor microenvironment, favors tumor survival and progression. Although hypoxia has been reported to play a major role in the acquisition of tumor resistance to cell death, the molecular mechanisms that control the survival of hypoxic cancer cells and the role of hypoxic stress in shaping the cross talk between immune cells and stroma components are not fully elucidated. Recently, several lines of investigation are pointing to yet another ominous outcome of hypoxia in the tumor microenvironment involving suppression of antitumor immune effector cells and enhancement of tumor escape from immune surveillance. Although the identification of tumor-associated antigens provided a new arsenal of approaches to enhance antigen-specific response, the immunotherapy approaches that are currently used in the clinic have only limited success. In fact, tumor stroma components including hypoxia are engaged in an active molecular cross talk that has serious implications for immunological recognition of tumor in shaping the microenvironment. In this review, we will focus on the impact of hypoxia on the regulation of the antitumor response and the subsequent tumor progression. We will also in particular discuss data that indicate that manipulation of hypoxic stress may represent an innovative strategy for a better immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142164     DOI: 10.1615/critrevimmunol.v31.i5.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  43 in total

Review 1.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 2.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

3.  Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression.

Authors:  Heqing Cui; Qin Qin; Meilin Yang; Hao Zhang; Zheming Liu; Yan Yang; Xiaochen Chen; Hongcheng Zhu; Di Wang; Cuicui Meng; Hongmei Song; Jianxin Ma; Guanhong Huang; Jing Cai; Xinchen Sun; Zhongming Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 4.  HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis.

Authors:  Yosra Messai; Muhammad Zaeem Noman; Meriem Hasmim; Bernard Escudier; Salem Chouaib
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

5.  Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.

Authors:  Ivy X Chen; Vikash P Chauhan; Jessica Posada; Mei R Ng; Michelle W Wu; Pichet Adstamongkonkul; Peigen Huang; Neal Lindeman; Robert Langer; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

Review 6.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

7.  Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling.

Authors:  Sadashib Ghosh; Arkoprovo Paul; Ellora Sen
Journal:  Mol Cell Biol       Date:  2013-05-13       Impact factor: 4.272

Review 8.  Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.

Authors:  S Chouaib; M Z Noman; K Kosmatopoulos; M A Curran
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

9.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

Review 10.  Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function.

Authors:  Eóin N McNamee; Darlynn Korns Johnson; Dirk Homann; Eric T Clambey
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.